innerbuddies gut microbiome testing

Gut Microbiome and Simple Steatosis (MASLD/NAFLD): How Microbiota Impacts Fatty Liver

Simple steatosis—often now framed within MASLD/NAFLD—happens when excess fat accumulates in liver cells. While genetics, insulin resistance, and diet are major drivers, your gut microbiome also plays a powerful supporting role. The trillions of microbes in your intestines help shape how you digest food, extract energy from meals, and regulate metabolic signals that influence liver fat storage.

Research suggests that certain gut bacteria and their byproducts can affect fatty liver through several “gut–liver” pathways. Changes in microbial balance may promote gut permeability (“leaky gut”), allowing inflammatory molecules to reach the liver via the bloodstream. Microbes also generate metabolites—such as short-chain fatty acids (SCFAs), bile acid derivatives, and other signaling compounds—that can either protect against or contribute to fat buildup depending on the overall microbiome profile.

The good news: the microbiome is modifiable. Diet patterns that increase fiber and plant diversity tend to support beneficial microbes and improve metabolic and anti-inflammatory signaling. By understanding how your gut ecosystem influences simple steatosis, you can make targeted, evidence-based choices that support healthier gut–liver communication—potentially helping slow progression from simple fat accumulation toward healthier liver outcomes.

Get Your Gut Microbiome Test Check your gut microbiome
innerbuddies gut microbiome testing

Simple steatosis

Simple steatosis is the buildup of excess fat inside liver cells with little or no liver inflammation or scarring. It is an early, common pattern of MASLD/NAFLD and is often asymptomatic, though mild elevations in liver enzymes (ALT/AST) and nonspecific symptoms like fatigue or right‑sided abdominal discomfort can occur. Globally, simple steatosis affects roughly a quarter to a third of adults, with higher rates among people with obesity, insulin resistance, or type 2 diabetes.

The gut microbiome plays a key role via the gut–liver axis. Shifts toward less favorable microbial profiles can alter production of metabolites such as short‑chain fatty acids and secondary bile acids, influence insulin signaling and hepatic fat handling, and reduce barriers that keep bacterial products from reaching the liver. A leaky gut and dysbiosis may promote low‑grade inflammation and mild liver enzyme elevations, even without overt inflammation or fibrosis. Diet is a major lever: higher, diverse fiber intake from vegetables, legumes, and whole grains, better fat and carbohydrate quality, and limiting ultra‑processed foods and added sugars can improve microbial function, gut barrier integrity, and liver metabolism. Probiotics or targeted prebiotics may help some individuals, but results vary by strain and overall diet pattern.

Microbiome testing like InnerBuddies can help link simple steatosis to gut–liver mechanisms, clarify whether dysbiosis or barrier impairment is contributing to metabolic stress, and guide personalized nutrition—focused on fiber diversity and whole foods—to improve gut signaling and liver health. The test can also help track changes in microbial diversity and metabolite pathways (e.g., SCFA and bile acid profiles) to monitor response over time, even though it does not replace imaging or liver enzyme data for diagnosing disease severity.

  • Butyrate-producing beneficial taxa (e.g., Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Lachnospiraceae NK4A136 group) help maintain gut barrier function and insulin sensitivity; their reduction is linked to simple steatosis.
  • Dysbiosis-associated elevated taxa (Escherichia coli, Enterococcus spp., Streptococcus spp., Ruminococcus gnavus group, Desulfovibrio spp., Bilophila wadsworthia) promote pro-inflammatory signaling (TLR/NF-κB) and altered bile acid metabolism that favor hepatic fat accumulation.
  • Microbial bile acid transformations regulate FXR/TGR5 signaling, influencing hepatic glucose handling and lipogenesis, contributing to fat storage in the liver.
  • Increased gut permeability ('leaky gut') allows endotoxins (LPS) to reach the liver, driving low-grade inflammation even without significant liver damage.
  • SCFA balance, particularly butyrate availability, modulates hepatic insulin signaling and lipid metabolism; shifts away from butyrate-producing pathways can worsen steatosis.
  • Dietary patterns that boost diverse dietary fiber and reduce ultra-processed foods can restore beneficial microbial outputs, improve gut barrier, and enhance gut–liver communication in simple steatosis.
  • Microbiome testing and personalized nutrition can guide targeted prebiotic strategies and track responses to interventions aimed at improving the gut–liver axis.
Get Your Gut Microbiome Test Check your gut microbiome
innerbuddies gut microbiome testing

MASLD / NAFLD spectrum

Simple steatosis refers to the buildup of excess fat within liver cells, often without significant liver inflammation or scarring. It is a common early pattern seen in MASLD/NAFLD (metabolic dysfunction–associated steatotic liver disease / nonalcoholic fatty liver disease). While genetics and insulin resistance matter, the gut microbiome has emerged as an important contributor to why fat accumulates in the liver and how quickly it progresses—through changes in metabolism, inflammation, and the “gut–liver axis” (signals and factors that move from the intestine to the liver via the bloodstream and bile pathways).

In people with simple steatosis, gut microbial composition and function can shift in ways that promote metabolic stress. Certain bacterial profiles are associated with greater production of microbial metabolites (such as short-chain fatty acids, secondary bile acids, and gut-derived inflammatory molecules) that can influence insulin signaling, fat storage, bile acid metabolism, and hepatic inflammation. Increased intestinal permeability (“leaky gut”) may also allow more bacterial products (for example, endotoxin/LPS) to reach the liver, stimulating inflammatory pathways even when overt damage is not yet present. At the same time, beneficial microbes that produce anti-inflammatory metabolites (including butyrate-related pathways) may be reduced, which can lessen protective signaling that supports gut barrier integrity and healthier lipid handling.

The good news is that gut-driven mechanisms are modifiable—meaning diet and lifestyle can meaningfully influence microbial activity and downstream liver effects. Evidence-based strategies include increasing dietary fiber (which feeds beneficial bacteria), prioritizing whole foods with diverse plant sources, choosing healthier fat and carbohydrate quality to improve insulin sensitivity, and limiting ultra-processed foods and excess added sugars that can worsen dysbiosis. Some people may also consider probiotics or targeted prebiotic strategies, but results vary by strain and overall diet pattern. Ultimately, supporting a healthier gut ecosystem can help reduce metabolic triggers for fat accumulation, improve gut barrier function, and better regulate gut–liver signaling—key steps in managing simple steatosis and supporting long-term liver health.

  • Often no symptoms (simple steatosis may be asymptomatic)
  • Fatigue or low energy
  • Right upper abdominal discomfort or dull pain
  • Bloating or indigestion
  • Unexplained weight gain or difficulty losing weight
  • Mildly elevated liver enzymes on blood tests (e.g., ALT/AST)
Get Your Gut Microbiome Test Check your gut microbiome
innerbuddies gut microbiome testing

Simple steatosis

This information is most relevant for people who have been told they have simple steatosis (fatty liver without major inflammation or scarring), especially in the context of MASLD/NAFLD, insulin resistance, prediabetes, or metabolic syndrome. It’s also a good fit if you’re trying to understand “why this is happening” beyond genetics—because gut microbiome changes (the gut–liver axis) can help explain how diet, metabolism, and intestinal barrier function can influence fat buildup in the liver.

It may be particularly helpful for individuals who are experiencing subtle symptoms sometimes associated with fatty liver—such as fatigue/low energy, dull right-upper-abdominal discomfort, bloating or indigestion, or difficulty losing weight. Since simple steatosis is often asymptomatic, the guidance is also relevant if your main clue has been mildly elevated liver enzymes (ALT/AST) on bloodwork, prompting you to look for actionable drivers and modifiable contributors.

This is relevant for anyone looking to improve liver health through gut-targeted, evidence-based lifestyle changes—like increasing dietary fiber and plant diversity, improving carbohydrate and fat quality for insulin sensitivity, and reducing ultra-processed foods and added sugars that may worsen dysbiosis. If you’re considering probiotics/prebiotics or want to understand why results vary, or you suspect “leaky gut” or inflammatory triggers may be part of your picture, the gut microbiome–focused perspective can help guide smarter next steps.

Simple steatosis (fatty liver without significant inflammation or scarring) is extremely common worldwide and represents the earliest and most prevalent pattern of MASLD/NAFLD. In population studies, overall NAFLD/MASLD affects roughly 25–30% of adults globally, with higher rates in people with obesity, insulin resistance, and type 2 diabetes—groups where prevalence often climbs to about 60–80%.

Prevalence varies by geography and diagnostic method (ultrasound vs. imaging vs. blood-based definitions), but the key point is that simple steatosis is frequently detected in otherwise asymptomatic adults. Because symptoms are often absent, many cases are found incidentally when liver enzymes (ALT/AST) are mildly elevated or during screening, which contributes to under-recognition even when the condition is present in a large portion of the population.

When simple steatosis is symptomatic, reports are typically nonspecific—such as fatigue/low energy, mild right upper abdominal discomfort, bloating/indigestion, or difficulty losing weight—so symptom-based estimates are unreliable. Still, real-world prevalence is strongly linked to cardiometabolic risk factors (particularly metabolic dysfunction), meaning that in adults with metabolic syndrome or type 2 diabetes, the likelihood of having fatty liver is substantially higher than in the general population, often approaching the majority depending on the subgroup and criteria used.

Get Your Gut Microbiome Test Check your gut microbiome
innerbuddies gut microbiome testing

Gut Microbiome and Simple Steatosis (MASLD/NAFLD): How Your Microbiota Impacts Fatty Liver

Simple steatosis (fat buildup in liver cells) is increasingly connected to the gut microbiome through the “gut–liver axis,” where microbial metabolites and signals travel via the bloodstream and bile pathways to influence liver fat handling. In many people, gut microbial communities shift toward patterns that promote metabolic stress—such as altered production of short-chain fatty acids, secondary bile acids, and other gut-derived molecules that can affect insulin signaling, lipid metabolism, and how efficiently the liver manages fat. Over time, these changes can support greater liver fat accumulation even when inflammation or scarring is not yet prominent.

Gut barrier function is another key pathway. When the intestinal lining becomes more permeable (“leaky gut”), bacterial products like endotoxin (LPS) may more easily reach the liver and trigger inflammatory signaling. This can contribute to mild liver enzyme elevations (ALT/AST) and help explain symptoms some people notice—such as fatigue or right upper abdominal discomfort—despite simple steatosis often being asymptomatic. At the same time, beneficial microbes involved in anti-inflammatory, gut-protective processes (including butyrate-related pathways) may be reduced, weakening protective signaling that supports barrier integrity and healthier metabolic regulation.

The encouraging part is that microbiome-driven effects are modifiable. Diet patterns that increase diverse fiber intake (from vegetables, legumes, whole grains, and other minimally processed plant foods) can feed beneficial microbes and improve metabolic and barrier-related signaling. Choosing carbohydrates with better quality, limiting added sugars and ultra-processed foods, and improving overall fat quality can support insulin sensitivity and reduce dysbiosis-associated liver triggers. Some people may explore probiotics or targeted prebiotics, but the most consistent benefits typically come from sustainable, whole-food dietary changes that improve microbial function and, in turn, gut–liver communication relevant to simple steatosis.

Get Your Gut Microbiome Test Check your gut microbiome
innerbuddies gut microbiome testing

Gut Microbiome and Simple steatosis

  • Gut–liver axis metabolic signaling: Microbial metabolites (e.g., short-chain fatty acids) and bile acid transformations can alter hepatic insulin sensitivity and lipid handling, promoting fat accumulation even without prominent inflammation.
  • Bile acid–microbiome crosstalk: Gut microbes convert primary to secondary bile acids, shifting signaling through receptors (e.g., FXR/TGR5) that regulate energy metabolism, glucose homeostasis, and hepatic lipogenesis.
  • Increased intestinal permeability (“leaky gut”): Barrier dysfunction can allow bacterial components (notably LPS/endotoxin) to reach the liver via portal circulation, driving low-grade inflammatory pathways that worsen metabolic dysfunction associated with steatosis.
  • Endotoxin-mediated inflammation (TLR/NF-κB signaling): Higher gut-derived endotoxin can activate hepatic immune signaling, impairing lipid oxidation and increasing cytokine-driven metabolic stress.
  • Reduced beneficial, anti-inflammatory microbe functions: Loss of fiber-fermenting and butyrate-producing pathways can weaken gut barrier integrity and reduce protective metabolites that support healthier metabolic regulation in the liver.
  • Altered gut-derived nutrient signaling: Changes in microbiome composition can influence intestinal production/availability of metabolites (e.g., acetate/propionate) that affect hepatic fat synthesis and peripheral insulin signaling.
  • Dysbiosis-associated changes in microbial ecology: Antibiotic exposure, low-fiber diets, and ultra-processed foods can reduce microbial diversity, shifting community functions toward metabolic stressors that favor progression of simple steatosis.

Simple steatosis—fat buildup in liver cells—is increasingly influenced by the gut microbiome through the gut–liver axis. Gut microbes can change the spectrum of metabolites and bile acid derivatives that reach the liver via the bloodstream and bile pathways. For example, microbial processing of dietary components affects short-chain fatty acids (like butyrate-related pathways) and alters primary bile acids into secondary bile acids. These compounds help regulate hepatic insulin sensitivity and lipid handling through signaling networks (including bile acid receptors such as FXR/TGR5), which can tip metabolism toward increased fat storage even when liver inflammation or scarring is not yet prominent.

Another key contributor is gut barrier function. When the intestinal lining becomes more permeable, bacterial products such as endotoxin (LPS) can more easily enter portal circulation and reach the liver. This can activate low-grade hepatic immune signaling (e.g., via TLR/NF-κB pathways), worsening metabolic dysfunction associated with steatosis and potentially nudging liver enzymes upward (ALT/AST) through inflammatory-metabolic cross-talk. At the same time, dysbiosis—often driven by low fiber intake, antibiotic exposure, and ultra-processed foods—may reduce beneficial, anti-inflammatory microbial functions that normally support barrier integrity and protective metabolites.

Over time, dysbiosis can reinforce a cycle that favors worsening steatosis. Reduced fiber fermentation and butyrate-related signaling can weaken barrier defenses, while altered microbial ecology can shift nutrient-related metabolite production (including different proportions of acetate/propionate) that influence hepatic fat synthesis and systemic insulin signaling. In parallel, bile acid–microbiome crosstalk can further modify glucose and energy regulation, changing the liver’s efficiency at oxidizing fat and managing lipids. Because these gut-derived signals are modifiable, targeting gut microbial function—most consistently through higher dietary fiber diversity and lower intake of added sugars and ultra-processed foods—may help improve gut–liver communication relevant to simple steatosis.

Get Your Gut Microbiome Test Check your gut microbiome
innerbuddies gut microbiome testing

Microbial patterns summary

In simple steatosis, the gut microbiome often shifts toward communities that produce a metabolite and bile-acid profile less supportive of metabolic health. Changes in microbial fermentation can alter short-chain fatty acid signaling (including butyrate-related pathways), and microbial processing of dietary compounds can shift the balance of bile acids—affecting how strongly hepatic fat and glucose handling are regulated through bile-acid receptors such as FXR and TGR5. Together, these altered outputs may promote insulin resistance and reduce the liver’s ability to efficiently oxidize or export lipids, even before significant inflammation or fibrosis is present.

A second common pattern involves weaker gut barrier function linked to dysbiosis. When the intestinal lining becomes more permeable, bacterial components such as endotoxin (LPS) are more likely to reach the liver via portal circulation, where they can drive low-grade inflammatory signaling (e.g., through TLR/NF-κB pathways). This can coincide with higher susceptibility to mild liver enzyme elevations (ALT/AST) and may reinforce metabolic dysfunction that favors fat accumulation. In many cases, the microbiome profile shows reduced activity of gut-protective, anti-inflammatory taxa and functions that normally help maintain tight junction integrity.

Over time, these microbial and metabolite shifts can form a self-reinforcing loop. Reduced intake of fermentable fiber and higher exposure to added sugars and ultra-processed foods can encourage an ecological pattern that favors dysbiosis, less butyrate production, and altered short-chain fatty acid ratios that influence hepatic lipid synthesis and systemic insulin signaling. Meanwhile, bile-acid transformations driven by the microbiome can further reshape glucose and energy regulation, changing the liver’s metabolic set points. Because these patterns are modifiable, diet-driven restoration of microbial diversity and fiber fermentation is often the most consistent way to improve gut–liver communication relevant to simple steatosis.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Butyrivibrio spp.
  • Bacteroides (Bacteroides fragilis group)
  • Akkermansia muciniphila
  • Parabacteroides distasonis
  • Lachnospiraceae_NK4A136_group


Elevated / overrepresented taxa

  • Escherichia coli (ETEC/Adherent-Invasive strains associated with dysmetabolism)
  • Enterococcus spp.
  • Streptococcus spp.
  • Bacteroides spp. (non-faecalibacterium bile-acid dysregulation-associated groups)
  • Ruminococcus gnavus group
  • Collinsella spp.
  • Desulfovibrio spp.
  • Bilophila wadsworthia


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis from dietary fiber, including butyrate-related pathways (reduced butyrate signaling via GPR41/43 and improved insulin sensitivity)
  • Bile acid transformation and secondary bile acid synthesis (microbial deconjugation/7α-dehydroxylation) affecting FXR and TGR5 signaling for hepatic lipid oxidation and glucose regulation
  • Gut barrier integrity and tight-junction maintenance pathways (microbial anti-inflammatory signaling that limits intestinal permeability)
  • Endotoxin (LPS) generation and LPS translocation-linked inflammatory signaling potential via TLR/NF-κB (driving low-grade portal inflammation that worsens metabolic dysfunction)
  • Microbial fermentation and carbohydrate metabolism toward dysmetabolic profiles (shifts in SCFA ratios and altered hepatic substrate availability)
  • Trimethylamine (TMA) and choline/carnitine metabolism to TMAO (bile-acid and metabolic cross-talk influencing insulin resistance and lipid handling)
  • Hydrogen sulfide (H2S) production and sulfur metabolism (e.g., Desulfovibrio/Bilophila-linked effects that may impair gut–liver metabolic regulation)


Diversity note

In simple steatosis, gut microbiome diversity often shifts toward a less resilient, more dysbiotic community structure. This can mean fewer beneficial, gut-protective taxa and functions that support anti-inflammatory signaling (including pathways tied to butyrate production), alongside relative enrichment of microbes that are better adapted to diets higher in refined carbohydrates and ultra-processed foods. The result is frequently a microbiome output profile that is less supportive of healthy lipid and glucose regulation through the gut–liver axis.

At the same time, reduced diversity is commonly associated with changes in microbial metabolism that affect short-chain fatty acids (SCFAs) and bile-acid transformation. When fermentation capacity declines or shifts, downstream SCFA signals—particularly those related to butyrate and a favorable SCFA balance—may weaken, which can influence insulin sensitivity and the liver’s handling of fat. Altered microbial processing of bile acids can also reshape signaling through bile-acid receptors (such as FXR and TGR5), further affecting hepatic energy metabolism.

Finally, lower diversity often correlates with impaired gut barrier function. A less diverse microbiome can reduce the availability of protective metabolites that help maintain tight junction integrity, making it easier for bacterial products (like endotoxin/LPS) to reach the liver via portal circulation. This can promote low-grade inflammatory signaling that tends to accompany metabolic stress and mild liver enzyme changes, reinforcing a cycle where dysbiosis and liver fat accumulation continue to influence each other.


Get Your Gut Microbiome Test Check your gut microbiome

Why generic solutions fail

  • Issue with generic solutions

    Generic approaches often fail in simple steatosis because the problem is usually not “fat in the liver” alone—it’s the metabolic signaling coming from the gut–liver axis. Broad advice like “eat healthier” or “try supplements” without targeting the specific drivers of dysbiosis (fiber type, meal patterns, and metabolic stressors) can miss the key mechanisms: altered microbial metabolite output (including SCFAs and bile-acid transformations) and downstream changes in insulin signaling and hepatic lipid handling. Without improving the quality and fermentability of carbohydrates and overall dietary consistency, the microbiome may not shift enough to restore bile-acid receptor signaling (e.g., FXR/TGR5) or improve the liver’s capacity to oxidize and export lipids efficiently.

    Another common reason generic solutions disappoint is that gut barrier dysfunction and low-grade portal inflammation are variable across individuals, so “one-size-fits-all” anti-inflammatory or probiotic strategies may not match the underlying barrier state. If the dominant issue is reduced gut-protective taxa or impaired tight-junction signaling, simply taking an unstructured probiotic blend may not meaningfully increase butyrate-associated pathways or reduce endotoxin (LPS) exposure to the liver. Conversely, if dysbiosis is being fueled by ongoing ultra-processed foods, alcohol, or low fiber intake, supplements can have minimal effect because the ecological pressure that caused the imbalance remains.

    Finally, generic plans often ignore that the gut–liver loop is self-reinforcing: diet composition influences microbial fermentation, which reshapes bile acids and inflammatory tone, which then further affects metabolism and liver fat storage. Generic “detox,” extreme restriction, or short-term interventions frequently don’t rebuild microbial diversity, gut fermentation capacity, and bile-acid profiles long enough to see durable changes. Without an approach that sustains fermentable fiber intake, improves fat and carbohydrate quality, and allows time for bile-acid and SCFA signaling to recalibrate, improvements—when they occur—tend to be inconsistent or temporary.

  • Common mistakes

    • Over-focusing on “removing liver fat” with generic clean-eating advice while ignoring gut–liver signaling drivers (SCFA and bile-acid transformation, FXR/TGR5-related metabolic regulation).
    • Relying on unstructured “healthy diet” messaging without specifying fermentable fiber quality/amount (and carbohydrate consistency), so the microbiome never meaningfully shifts toward beneficial fermentation outputs (e.g., butyrate-associated pathways).
    • Using probiotic or supplement stacks without addressing ecological pressure (ultra-processed foods, low fiber intake, irregular meal patterns, alcohol), limiting whether helpful taxa can actually persist and function.
    • Assuming all patients share the same dominant mechanism; not accounting for variable gut barrier dysfunction/endotoxin (LPS) permeability that may require barrier-supportive nutrition patterns rather than one-size anti-inflammatory tactics.
    • Thinking short-term interventions or “detox” cycles can reset bile-acid and SCFA signaling quickly, despite the self-reinforcing gut–liver loop that requires sustained dietary rebuilding of microbial diversity/fermentation capacity.
    • Neglecting meal pattern and metabolic stressors (e.g., high added sugars, late eating, large glycemic spikes) that continue to worsen insulin resistance and hepatic lipid handling even if some foods are “healthier.”
    • Skipping attention to bile-acid–related outcomes (not just calorie restriction), leading to incomplete normalization of microbiome-driven bile-acid profiles that govern glucose and lipid regulation through hepatic receptors.

What to do

  • General support strategies

    Simple steatosis is increasingly understood through the gut–liver axis, where gut microbes and their metabolites influence how the liver handles fat and insulin signaling. A cornerstone strategy is to support a healthier, more diverse gut microbiome by increasing dietary fiber from minimally processed plant foods such as vegetables, legumes, whole grains, nuts, and seeds. This helps nourish beneficial microbes and encourages metabolite profiles linked to improved metabolic regulation, including protective short-chain fatty acid–related pathways. At the same time, emphasizing higher-quality carbohydrates (e.g., less added sugar and fewer ultra-processed foods) can reduce dysbiosis-associated metabolic stress that can contribute to liver fat accumulation.

    Another key area is gut barrier function. When the intestinal lining becomes more permeable, bacterial components such as endotoxin (LPS) may more easily reach the liver and promote inflammatory signaling, which can worsen liver enzyme elevations even in earlier or “simple” disease states. Supporting the barrier often overlaps with microbiome-friendly nutrition: adequate fiber and plant polyphenols, sufficient overall protein, and healthy fat sources can help sustain gut integrity and reduce the likelihood of pro-inflammatory signaling. Hydration and consistent eating patterns may also indirectly support gut function by promoting regular bile flow and microbial stability.

    While supplements like probiotics or targeted prebiotics may be considered in some cases, the most reliable improvements typically come from long-term dietary changes that are easy to maintain. Creating a diet pattern that improves insulin sensitivity and lipid metabolism—through fiber-rich foods, reduced added sugars, and better fat quality (such as olive oil, nuts, and omega-3–containing foods)—can enhance beneficial gut–liver communication. Over time, these approaches may support healthier liver fat handling and reduce factors that drive metabolic and inflammatory signaling during the progression of steatosis.

  • Lifestyle recommendations

    • Increase dietary fiber (aim for a variety of vegetables, legumes, whole grains, nuts/seeds) to support a healthier gut microbiome and improve gut–liver signaling.
    • Limit added sugars, refined carbs, and ultra-processed foods to reduce metabolic stress that can worsen liver fat accumulation.
    • Prioritize healthy fats (e.g., olive oil, nuts, seeds, fatty fish) and reduce intake of trans fats and excess saturated fats.
    • Maintain a healthy body weight and incorporate regular physical activity (a mix of aerobic exercise and resistance training) to improve insulin sensitivity and reduce hepatic fat.
    • Avoid or minimize alcohol (or abstain if steatosis is alcohol-associated) and discuss any current alcohol intake with your clinician.
    • Support gut barrier health by staying well-hydrated, managing chronic constipation, and avoiding smoking; consider addressing reflux/dysbiosis contributors with a clinician if relevant.
    • Consider discussing a clinician-guided approach to probiotics or targeted prebiotics only after dietary changes, especially if you have GI symptoms—avoid “megadose” supplements without guidance.

  • Nutrition recommendations

    • Increase dietary fiber to support a healthier gut–liver axis (aim for a mix of soluble + insoluble fiber): vegetables, legumes (beans/lentils), whole grains (oats, barley, brown rice), chia/flax—while gradually increasing to avoid GI discomfort.
    • Prioritize minimally processed, whole-food carbohydrates and reduce added sugars/ultra-processed foods to improve insulin sensitivity and reduce dysbiosis signals linked to liver fat accumulation.
    • Choose unsaturated fats over saturated/trans fats: olive oil, avocado, nuts, seeds, and fatty fish (salmon/sardines) to support better lipid handling and metabolic signaling.
    • Support gut barrier health with fiber-rich plant diversity and fermented foods (e.g., yogurt with live cultures, kefir, sauerkraut, kimchi) when tolerated; consider targeting foods that provide beneficial metabolites rather than relying on supplements alone.
    • Limit alcohol and keep caffeine/energy drinks moderate (especially avoiding sugar-sweetened options), since alcohol and high sugar load can worsen fatty liver risk and gut permeability.
    • Use a “plate method” at most meals (½ non-starchy vegetables, ¼ lean protein, ¼ high-fiber whole grain/starchy vegetable) to help control post-meal glucose and reduce metabolic stress that drives steatosis.

  • Supplement considerations

    For simple steatosis, supplement strategies often focus on supporting the gut–liver axis—mainly by improving microbial metabolic output and strengthening gut barrier integrity. The most consistently relevant approach is to provide “fuel” for beneficial microbes (e.g., fermentable fibers/prebiotics) rather than relying on single compounds. Prebiotic options such as inulin, partially hydrolyzed guar gum, resistant starch, or PHGG can increase production of beneficial short-chain fatty acids (including butyrate), which support intestinal barrier function and may improve insulin sensitivity and lipid handling in the liver. These gut-derived signals are thought to influence how efficiently the liver manages fat and glucose metabolism, potentially helping reduce the drivers of fat accumulation.

    Targeted probiotic supplementation may also be considered, but results vary by strain and individual baseline microbiome. In steatosis, probiotics are typically explored for their potential to shift microbial balance away from more pro-metabolic-stress patterns and toward more anti-inflammatory, barrier-supporting profiles. Some formulations are designed to affect bile acid metabolism and gut-derived signaling pathways that can influence liver fat deposition. If choosing probiotics, it’s generally more practical to pick evidence-informed multi-strain products and use them consistently for a trial period while monitoring tolerance, as gas/bloating can occur—especially when starting prebiotics.

    Finally, several supplements are used as adjuncts to address mechanisms linked to gut–liver inflammation, such as endotoxin (LPS) signaling. Options like omega-3 fatty acids (for metabolic and hepatic fat effects), and antioxidants (to support oxidative stress balance) may complement microbiome-focused choices, although they do not replace diet-driven improvements. If using any supplement, it’s wise to coordinate timing with meals and consider liver-friendly basics (adequate protein, limited alcohol, reduced added sugars and ultra-processed foods). Because steatosis can coexist with other metabolic conditions, the most effective supplement plan is usually the one that supports insulin sensitivity and gut barrier function while staying aligned with clinician-directed monitoring of liver enzymes.

  • Retesting / monitoring note

    For simple steatosis, retesting is typically aimed at confirming that liver fat is not progressing and that metabolic risk factors are being addressed. After an initial diagnosis, many clinicians reassess within about 3–6 months, especially if lifestyle changes are being implemented. Repeat testing often combines a liver enzyme panel (ALT/AST), metabolic markers (such as fasting glucose, HbA1c, and a lipid profile), and a noninvasive liver fat assessment when available (e.g., ultrasound or fibrosis-risk scoring). If results improve, follow-up may be spaced out; if enzymes remain elevated or risk is high, earlier and more frequent monitoring may be considered.

    Because the gut–liver axis is increasingly relevant to steatosis, retesting may also focus on drivers that plausibly affect microbial metabolites and gut barrier integrity. A practical approach is to reassess after dietary adherence that supports microbiome diversity—typically high-fiber, minimally processed foods—with reduced added sugars and refined carbohydrates. Some patients opt for stool-based microbiome testing or gut barrier–related markers, but these are not universally standardized; when used, they’re best interpreted alongside liver labs and metabolic outcomes. The key goal of retesting is to determine whether improvements in insulin sensitivity, lipid handling, and inflammatory signaling correlate with better liver status.

    If there are persistent abnormalities on repeat labs, retesting should be extended beyond basic enzymes to evaluate for alternative causes or coexisting conditions (for example, viral hepatitis, medication-related fatty liver, or other metabolic liver diseases). Clinicians may also consider fibrosis risk evaluation (noninvasive scoring tools, and in select cases transient elastography) rather than repeating liver fat imaging alone. In general, retesting should be coordinated with a healthcare professional so the frequency and choice of tests match baseline severity, age, comorbidities, and whether the microbiome- and metabolism-focused interventions are producing measurable benefit.

The importance of gut microbiome testing

  • Why testing matters

    For simple steatosis, gut microbiome testing can be valuable because it helps clarify whether the gut–liver axis is likely contributing to fat accumulation and metabolic stress. The microbiome influences how the body handles bile acids, insulin signaling, and lipid metabolism through microbial metabolites (including short-chain fatty acids and secondary bile acids) that travel to the liver. By identifying patterns associated with dysbiosis—such as reduced beneficial, gut-protective communities or shifts that may promote less favorable bile acid signaling—testing can translate “fat in the liver” into a more actionable, gut-linked mechanism rather than a purely liver-centric one.

    Gut barrier integrity is another reason microbiome data can matter. If testing suggests a microbiome pattern linked to impaired gut lining function, it may indicate a higher likelihood of microbial products like endotoxin reaching the liver and nudging inflammatory signaling (even without advanced scarring). This can help explain why some individuals experience mild enzyme elevations or nonspecific symptoms such as fatigue despite being classified as having simple steatosis. Understanding your baseline microbial signals can therefore support more targeted diet and lifestyle strategies aimed at improving barrier function and reducing gut-derived inflammatory triggers.

    Finally, microbiome testing can guide personalization and track response to interventions. Because the most consistent improvements in gut–liver communication often come from fiber-rich, minimally processed dietary changes, testing can help determine whether you’re getting a microbiome shift in the right direction—such as increased microbial diversity and improved metabolite profiles. While testing isn’t a standalone diagnostic for steatosis severity, it can make your nutrition plan more precise, helping you choose the right prebiotic fibers and food patterns and monitor whether gut-driven contributors are improving alongside your liver health.

  • How InnerBuddies helps

    The InnerBuddies test helps you connect simple steatosis to actionable gut–liver mechanisms by looking at your gut microbial patterns—those communities that influence bile acid signaling, insulin sensitivity, and how efficiently your body metabolizes fats. Because microbes produce metabolites such as short-chain fatty acids and secondary bile acids that can affect liver fat handling, the results can clarify whether your current microbiome composition is more consistent with metabolic stress-promoting pathways or with a more protective, balanced gut ecosystem.

    In addition, InnerBuddies can provide insight into factors that relate to gut barrier integrity, which is a key part of the gut–liver axis. When the intestinal lining is less resilient, microbial products like endotoxin (LPS) may be more likely to reach the liver and contribute to low-grade inflammatory signaling and mild liver enzyme elevations. By identifying microbiome signals associated with reduced anti-inflammatory, barrier-supportive functions (for example, pathways linked to beneficial fermentation), the test can help you understand whether gut-derived triggers may be part of your steatosis picture—even when imaging or labs suggest “simple” fat without significant scarring.

    Finally, the InnerBuddies results can support personalization and follow-through. Since many of the most consistent improvements for gut–liver communication come from specific, sustainable dietary changes—especially increasing diverse, fiber-rich whole foods while limiting added sugars and ultra-processed patterns—the test offers a way to choose prebiotic fibers and food strategies more deliberately. It can also be used to track whether your microbiome is shifting toward profiles associated with improved gut signaling, which may align with better metabolic and liver outcomes over time.

Medical Evidence

  • Scientific evidence level

    2 [weak; emerging but inconsistent]

  • Clinical relevance note

    Clinical utility (biomarker/diagnostic/patient stratification/monitoring) is currently weak. Although microbiome signatures differ on average between people with NAFLD and controls, there is no widely validated, externally reproducible stool-based microbiome metric that reliably diagnoses “simple steatosis” specifically, predicts its onset/progression beyond established clinical risk factors (BMI, diabetes status, insulin resistance, imaging/labs), or guides treatment selection in routine practice. Reproducibility across cohorts is a concern, and stool microbiome may not reflect the relevant hepatic/mucosal environment.

    From a causality perspective, the most critical gap is that many human studies cannot distinguish whether microbiome changes are a driver, a consequence of hepatic fat/metabolic changes, or a reflection of shared upstream factors (dietary patterns, obesity, insulin resistance, medications such as metformin and statins, gut permeability, and bile acid differences). Reverse causality and residual confounding are plausible. Because of these limitations, current clinical relevance is mainly conceptual: the microbiome may contribute to risk or pathophysiology, but it is not yet actionable for diagnosing or managing simple steatosis.

Title Journal Year Link
Association between gut microbiome and nonalcoholic fatty liver disease: a meta-analysis Frontiers in Microbiology 2020 View →
Gut microbiota and liver disease: from mechanistic insights to clinical perspectives Nature Reviews Gastroenterology & Hepatology 2016 View →
Gut microbiome composition and function influence metabolic health Nature Reviews Endocrinology 2013 View →
Changes in the gut microbiome in nonalcoholic fatty liver disease Nature Medicine 2012 View →
Gut microbiota in nonalcoholic fatty liver disease and cirrhosis Hepatology 2011 View →

Frequently Asked Questions

    Qu’est-ce que la steatose simple ?
    La steatose simple est une accumulation de graisse dans les cellules du foie sans inflammation ou cicatrisation significatives; c’est un profil précoce de MASLD/NAFLD. C’est une information générale et ce n’est pas un avis médical; consultez un médecin pour des conseils adaptés.
    Comment la steatose simple est‑elle liée au microbiote intestinal ?
    Le microbiote intestinal communique avec le foie via l’axe intestin‑foie et influence le stockage des graisses et la signalisation de l’insuline. Une dysbiose peut favoriser l’accumulation de graisse. C’est une information générale et non un conseil médical.
    Quels symptômes peut présenter une steatose simple ?
    La plupart des personnes n’ont pas de symptômes; certains peuvent ressentir de la fatigue, une douleur légère en haut à droite, des ballonnements ou des légères élévations des enzymes hépatiques. C’est une information générale et non un avis médical.
    Quelle est la fréquence de la steatose simple ?
    Très courante et caractéristique du MASLD/NAFLD. Souvent associée à l’obésité et à la résistance à l’insuline. C’est une information générale et non un avis médical.
    Un test du microbiote peut‑il m’aider ?
    Un test peut indiquer des liens intestin‑foie et guider des idées diététiques, mais ce n’est pas un diagnostic à lui seul. À utiliser avec d’autres informations cliniques. C’est une information générale et non un avis médical.
    Quels changements alimentaires aident l’axe intestin‑foie ?
    Augmenter les fibres alimentaires variées d’origine végétale, privilégier des aliments peu transformés et complets, améliorer la qualité des graisses et limiter les sucres ajoutés et les aliments ultratransformés. C’est une information générale et non un avis médical.
    Les probiotiques ou prébiotiques sont‑ils utiles ?
    Les preuves varient selon la souche et le régime; ils peuvent faire partie d’un mode de vie sain, mais discutez‑en avec votre médecin. C’est une information générale et non un avis médical.
    Quels mécanismes relient le microbiote au foie ?
    Des métabolites microbien tels que les SCFA et les transformations des acides biliaires influencent la sensibilité à l’insuline et le métabolisme des lipides. C’est une information générale et non un avis médical.
    Comment suivre mes progrès ?
    Consultations régulières pour les tests hépatiques et éventuellement l’imagerie; suivre le poids et l’alimentation. Une analyse du microbiote peut être répétée si elle fait partie du plan. C’est une information générale et non un avis médical.
    La steatose simple peut‑elle progresser vers une maladie grave ?
    Oui, une progression est possible en présence d’inflammation ou de fibrose; les changements de mode de vie peuvent réduire le risque. C’est une information générale et non un avis médical.
    Y a‑t‑il des médicaments pour traiter la steatose simple ?
    Il n’existe pas de médicament spécifique approuvé pour la steatose simple; la gestion se concentre sur le mode de vie et le traitement des facteurs de risque métaboliques. C’est une information générale et non un avis médical.
    Quelle est la différence entre steatose simple et MASLD/NAFLD ?
    La steatose simple est une graisse dans les cellules hépatiques sans inflammation marquée; MASLD/NAFLD est une catégorie plus large incluant la dysfonction métabolique. C’est une information générale et non un avis médical.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -